市场调查报告书
商品编码
1466547
间质干细胞市场:按类型、适应症、分离来源、应用分类 - 2024-2030 年全球预测Mesenchymal Stem Cells Market by Type (Allogeneic, Autologous), Indication (Bone & Cartilage Repair, Cancer, Cardiovascular Disease), Source of Isolation, Application - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
间质干细胞市场规模预计2023年为35.1亿美元,2024年达39.8亿美元,预计2030年将达到85.9亿美元,复合年增长率为13.63%。
间质干细胞(MSC)是多功能基质细胞,可分化成各种细胞类型,如成骨细胞、软骨细胞、肌肉细胞和脂肪细胞。这些细胞透过其黏附于塑胶表面的能力以及在特定条件下培养时特定表面标誌物的表达来识别。间质干细胞从多种组织中采集,包括骨髓、脂肪组织、脐带血和牙髓。推动间质干细胞扩大用途的关键因素包括其可再生、免疫调节特性以及在治疗骨关节炎、心血管疾病和移植物抗宿主疾病等各种疾病中的用途。此外,再生医学和作为基因治疗的递送载体的新应用的潜力进一步增加了研究和工业界的兴趣。然而,MSC的使用存在免疫排斥的风险和恶性的可能性。为了解决这些问题,间质干细胞分离和培养技术的标准化以及开发稳健的体外扩增和品管通讯协定非常重要。组织工程的进步和3D生物列印技术的发展可能使利用间质干细胞建构复杂的组织和器官成为可能。此外,对个人化医疗的日益重视可能会带来更有针对性和更有效的基于间质干细胞的治疗。
主要市场统计 | |
---|---|
基准年[2023] | 35.1亿美元 |
预测年份 [2024] | 39.8亿美元 |
预测年份 [2030] | 85.9亿美元 |
复合年增长率(%) | 13.63% |
自体间质干细胞具有免疫安全性和个人化性质,有利于长期治疗。
同种异体间质干细胞源自供体,经过扩增和储存以供各种受体使用。这些细胞在扩充性和即时可用性方面具有优势,这在急性护理环境中非常重要。当患者需要立即介入并且没有时间或能力捐赠自己的细胞时,通常需要使用同种异体 MSC。此外,健康状况不佳或某些遗传性疾病的患者可能会从同种异体间质干细胞中获益更多,以避免使用潜在不健康细胞的风险。由于自体间质干细胞是从患者自身体内收集的,因此它们出现免疫排斥的可能性较小,并且避免了与捐赠者采购相关的伦理考量。当计划治疗时,例如慢性或退化性疾病疾病,自体 MSC 是首选。这种个体化确保了相容性并降低了免疫反应的风险。
用于 CVD 治疗适应症的 MSC 的大量研发活动
骨关节炎、类风湿性关节炎和骨质疏鬆症的盛行率不断增加,以及改善骨折癒合的需要,推动了骨骼和软骨修復对 MSC 的需求。间质干细胞至关重要,因为它们有可能分化成成骨细胞和软骨细胞,从而为修復受损的骨骼和软骨组织提供再生选择。间质干细胞代表了一种新的癌症治疗方法,特别是因为它们具有肿瘤部位的归巢能力和抗癌药物传递的潜力。心血管疾病 (CVD) 是全世界死亡的主要原因,间质干细胞因其再生受损心臟组织的潜力而受到关注。由于心臟组织的再生能力有限,因此对这种应用的需求非常迫切。移植物抗宿主疾病(GvHD)是造血干细胞移植的严重併发症。 MSC具有免疫调节特性,适合治疗GvHD。间质干细胞的免疫调节作用有潜力作为治疗自体免疫疾病和发炎疾病(如多发性硬化症、红斑性狼疮和克隆氏症)的药物。这些疾病是慢性的,现有的治疗方法不足,因此迫切需要新的治疗方法。肝硬化、肝炎等肝病都会导致肝功能衰竭,肝臟移植是唯一的治疗方法。间质干细胞疗法可以透过促进肝臟再生和纤维化修復来提供一种侵入性较小的替代疗法。
分离来源:骨髓间质干细胞的高细胞产量和已建立的治疗用途
脂肪组织来源的间质干细胞(AD-MSCs)通常是在抽脂过程中从脂肪组织中收穫的。 AD-MSCs丰富且易于收穫,每克组织的MSCs产量高。 AD-MSC 表现出强大的分化潜力,是再生医学和化妆品应用的理想选择。骨髓间质干细胞(BM-MSCs)因其高分化潜力而成为研究最广泛的间质干细胞之一。骨髓间质干细胞常用于治疗血液疾病以及修復骨骼和软骨。脐带血来源的间质干细胞是从出生后的脐带血中收集的。脐带血来源的间质干细胞比其他来源的间质干细胞成熟度较低,可能会影响其免疫调节功能。从输卵管分离出的间质干细胞由于其胚胎样特性而成为再生医学中有前途的新来源。胎儿肝臟来源的 MSC 因其高增殖率和产生各种细胞类型的潜力而被鑑定。其用途主要集中在研究,特别是肝病和肝再生。肺源性间质干细胞由于其部位特异性优势,可用于呼吸系统疾病的研究与治疗。从週边血液中采集的间质干细胞具有透过侵入性较小的过程采集的优点。週边血液来源的 MSC 是骨髓和脂肪组织来源的 MSC 的非侵入性替代品,但周边血液中 MSC 的浓度要低得多,这使得它们难以分离,并可能限制临床应用。
间质干细胞由于能够模拟人类应用疾病并测试药物疗效,在疾病建模和药物发现方面具有优势
间质干细胞越来越多地用于疾病建模,以了解各种疾病的病理学。研究人员优先利用间质干细胞,因为它们能够分化成多种细胞类型并具有免疫调节特性。间质干细胞在药物开发和药物发现的早期阶段发挥重要作用。它们的分化潜力使研究人员能够观察新药对 MSC 衍生的各种细胞类型的影响。这对于发现新治疗方法和了解药物机制至关重要。干细胞银行正成为间质干细胞的重要应用,私人和公共银行为未来的治疗应用提供储存服务。组织工程是一个不断发展的领域,间质干细胞对于开发修復或替换受损组织的生物替代品至关重要。 MSC 也用于体外毒性测试,以评估化学物质和药物的安全性。间质干细胞的多功能使其特别适合预测多种细胞类型的毒性。
区域洞察
参与间质干细胞(MSC)研究和治疗开发的生物技术公司在美洲,特别是在美国和加拿大拥有强大的影响力,这得益于细胞治疗产品的大量投资和有利的监管趋势。在FDA对干细胞治疗和先进医疗基础设施的前瞻性立场的推动下,这些国家越来越多地将间质干细胞用于骨关节炎、创伤治疗和移植物抗宿主疾病等临床试验。在以中国、日本和韩国为代表的亚太地区,人们对间质干细胞的兴趣不断增长且迅速增长,各国政府积极推动再生医学作为科学进步的重要领域。亚太地区的公司正在大力投资扩大生产能力并建立国际合作,以加强间质干细胞的研究和临床应用。欧洲、中东和非洲地区的情况好坏参半,欧洲国家也遵守与美洲类似的严格监管标准。欧洲药品管理局 (EMA) 提供全面的法规结构,确保 MSC 产品的安全性和有效性。然而,欧洲有一些专门从事干细胞研究的先驱公司和研究机构,非常注重品质和製造控制以及品管规范(GMP)的遵守。
FPNV定位矩阵
FPNV定位矩阵对于评估间质干细胞市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对间质干细胞市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,以获得市场竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争力评估及资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.间质干细胞市场规模及预测为何?
间质干细胞市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些?
3.间质干细胞市场的技术趋势和法规结构是什么?
4.间质干细胞市场主要厂商的市场占有率为何?
5.进入间间质干细胞市场的合适型态和策略性手段是什么?
[189 Pages Report] The Mesenchymal Stem Cells Market size was estimated at USD 3.51 billion in 2023 and expected to reach USD 3.98 billion in 2024, at a CAGR 13.63% to reach USD 8.59 billion by 2030.
Mesenchymal stem cells (MSCs) are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, and adipocytes. These cells are identified by their ability to adhere to plastic surfaces when cultured under specific conditions and by the expression of certain surface markers. MSCs are harvested from various tissues, including bone marrow, adipose tissue, umbilical cord blood, and dental pulp. The major factors driving the expansion of their use include their regenerative potential, immunomodulatory properties, and their use in treating various diseases, such as osteoarthritis, cardiovascular disease, and graft-versus-host disease. Additionally, their potential in emerging regenerative medicine applications and as delivery vehicles for gene therapy has further catalyzed research and industry interest. However, there is a risk of immune rejection and potential for malignant transformation with the use of MSCs. To address these issues, standardization of MSC isolation and culture techniques is critical, as well as the development of robust protocols for in vitro expansion and quality control. Advances in tissue engineering and the development of 3D bioprinting technologies may allow for the construction of complex tissues and organs using MSCs. Additionally, the growing emphasis on personalized medicine is likely to lead to more targeted and effective MSC-based therapies.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.51 billion |
Estimated Year [2024] | USD 3.98 billion |
Forecast Year [2030] | USD 8.59 billion |
CAGR (%) | 13.63% |
Type: Immunological safety and personalized nature of autologous MSCs to make them beneficial for long-term treatments
Allogeneic MSCs are derived from a donor, which are then expanded and stored for use in different recipients. These cells have an advantage in scalability and immediate availability, which is critical in acute care scenarios. Allogeneic MSCs are often indicated in cases where patients require immediate intervention and may not have the time or ability to donate their own cells. In addition, individuals with compromised health or certain genetic disorders may benefit more from allogeneic MSCs to avoid the risks of using their potentially unhealthy cells. Autologous MSCs are harvested from the patient's own body, which diminishes the likelihood of immune rejection and avoids the ethical considerations associated with donor sourcing. Autologous MSCs are preferred in chronic conditions or when treatments are planned, such as for degenerative diseases. This personalization ensures compatibility and a lower risk of immune response.
Indication: Substantial research and development activities on MSCs for the treatment of CVDs
The need for mesenchymal stem cells (MSCs) in bone and cartilage repair is driven by the increasing prevalence of osteoarthritis, rheumatoid arthritis, and osteoporosis, as well as the necessity for improved healing of bone fractures. MSCs are pivotal for their potential to differentiate into osteoblasts and chondrocytes, thereby providing a regenerative option for repairing damaged bone and cartilaginous tissues. MSCs represent a novel therapeutic approach for cancer treatment, particularly due to their homing capabilities to tumor sites and their potential to deliver anti-cancer agents. Cardiovascular diseases (CVD) are a leading cause of death globally, and MSCs have gained attention for their potential to regenerate damaged heart tissue. The need for this application is pressing due to the limited regenerative capacity of the cardiac tissue. Graft-versus-host disease (GvHD) is a severe complication of hematopoietic stem cell transplantation. MSCs have immunomodulatory properties that make them a suitable treatment for managing GvHD. MSCs' immunomodulatory effects serve as a potential therapy for autoimmune and inflammatory diseases such as multiple sclerosis, lupus, and Crohn's disease. These conditions have a high need for new therapies due to their chronic nature and the inadequacy of existing treatments. Liver diseases, such as cirrhosis and hepatitis, can lead to liver failure, for which liver transplantation is the only definitive treatment. MSC therapies could offer a less invasive alternative by promoting liver regeneration and fibrosis repair.
Source of Isolation: High cell yield and established therapeutic use of bone-marrow derived MSC
Adipose tissue-derived MSCs (AD-MSCs) are obtained from fat tissues, often during liposuction procedures. They are abundant and easy to harvest, with a high yield of MSCs per gram of tissue. AD-MSCs exhibit a strong capacity for differentiation, making them ideal for regenerative medicine and cosmetic applications. Bone marrow-derived MSCs (BM-MSCs) are one of the most extensively studied MSC types due to their high differentiation potential. They are often used in treating hematological diseases and repairing bone and cartilage. Cord blood-derived MSCs are collected from the umbilical cord blood after childbirth, a non-invasive and ethically uncontroversial source. They are less mature than MSCs from other sources, which may have implications for their immunomodulatory functions. Mesenchymal stem cells isolated from the fallopian tube are a novel source with a promising future in regenerative medicine due to their embryonic-like properties. Fetal liver-derived MSCs have been identified for their high proliferation rate and potential to generate a variety of cell types. Their use is primarily research-focused, with particular interest in liver diseases and hepatic regeneration. Lung-derived MSCs are valuable for studying and treating respiratory diseases due to their site-specific advantages. Mesenchymal stem cells obtained from peripheral blood have the advantage of being harvested through a less invasive process. They offer a non-invasive alternative to bone marrow and adipose tissue sources, but the MSCs found in peripheral blood are in far lower concentrations, which can complicate isolation and limit their clinical applications.
Application: Benefits of MSCs in disease modeling and drug discovery due to their ability to mimic human diseases and test drug efficacy
MSCs are increasingly being utilized in disease modeling to understand the pathophysiology of various disorders. Researchers prioritize MSCs for their ability to differentiate into multiple cell types and for their immunomodulatory properties. MSCs play a crucial role in the early phases of drug development and discovery. Their differentiation capabilities enable researchers to observe the effects of new drugs on various cell types derived from MSCs. This is essential for discovering new therapies and understanding drug mechanisms. Stem cell banking has emerged as an important application for MSCs, with private and public banks offering storage services for future therapeutic use. Tissue engineering is a growing field where MSCs are essential for the development of biological substitutes to repair or replace damaged tissues. MSCs are also used for in vitro toxicology studies to evaluate the safety of chemicals and drugs. MSCs' multipotency makes them particularly suited for predicting toxicity in multiple cell types.
Regional Insights
In the Americas, particularly the United States and Canada, there is a robust presence of biotechnology firms engaged in mesenchymal stem cell (MSCs) research and therapy development, supported by significant investment and favorable regulatory pathways for cell therapy products. These countries are major in clinical trials involving MSCs, focusing on applications such as osteoarthritis, wound healing, and graft-versus-host disease, propelled by the FDA's progressive stance on stem cell therapies and advanced healthcare infrastructure. The APAC region, led by countries such as China, Japan, and South Korea, showcases a dynamic and rapidly growing interest in MSCs, with governments actively promoting regenerative medicine as a key area for scientific advancement. APAC companies are investing heavily in scaling up manufacturing capabilities and in establishing international collaborations to enhance both research and clinical application of MSCs. The EMEA region presents a mixed scenario, with European countries adhering to stringent regulatory standards similar to those in the Americas. The European Medicines Agency (EMA) offers a comprehensive regulatory framework that ensures the safety and efficacy of MSC products. Nonetheless, Europe is home to several pioneering companies and research institutions dedicated to stem cell research, with a focus on quality and adherence to Good Manufacturing Practice (GMP) standards.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Mesenchymal Stem Cells Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Mesenchymal Stem Cells Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Mesenchymal Stem Cells Market, highlighting leading vendors and their innovative profiles. These include AMS Biotechnology, Astellas Pharma Inc., Athersys, Inc., Axol Biosciences Ltd., BrainStorm Cell Therapeutics Inc., Cell Applications, Inc., Celprogen, Inc., Cyagen Biosciences, Inc., Cytori Therapeutics Inc., Genlantis, Inc., Globus Medical, Hope Biosciences, LLC, Lonza Group AG, Merck KGaA, Mesoblast Limited, Neuromics, Pluri Biotech Ltd., PromoCell GmbH, R&D Systems, Inc., ScienCell Research Laboratories, Inc., Smith & Nephew PLC, Stemcell Technologies Inc., Stemedica Cell Technologies, Inc., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., and Vericel Corporation.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Mesenchymal Stem Cells Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Mesenchymal Stem Cells Market?
3. What are the technology trends and regulatory frameworks in the Mesenchymal Stem Cells Market?
4. What is the market share of the leading vendors in the Mesenchymal Stem Cells Market?
5. Which modes and strategic moves are suitable for entering the Mesenchymal Stem Cells Market?